164 related articles for article (PubMed ID: 38056899)
1. Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.
Phadke MS; Li J; Chen Z; Rodriguez PC; Mandula JK; Karapetyan L; Forsyth PA; Chen YA; Smalley KSM
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056899
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
[TBL] [Abstract][Full Text] [Related]
3. In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.
Clark PA; Sriramaneni RN; Jin WJ; Jagodinsky JC; Bates AM; Jaquish AA; Anderson BR; Le T; Lubin JA; Chakravarty I; Arthur IS; Heinze CM; Guy EI; Kler J; Klar KA; Carlson PM; Kim KM; Kuo JS; Morris ZS
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690669
[TBL] [Abstract][Full Text] [Related]
4. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
[TBL] [Abstract][Full Text] [Related]
7. Higher frequency of the CTLA-4
Chen Y; Tan J; Huang S; Huang X; Huang J; Chen J; Yu Z; Lu Y; Weng J; Du X; Li Y; Zha X; Chen S
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e12-e18. PubMed ID: 31612643
[TBL] [Abstract][Full Text] [Related]
8. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
[TBL] [Abstract][Full Text] [Related]
9. PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4
Goding SR; Wilson KA; Rosinsky C; Antony PA
J Immunol; 2018 May; 200(9):3304-3311. PubMed ID: 29602773
[TBL] [Abstract][Full Text] [Related]
10. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.
Belcaid Z; Phallen JA; Zeng J; See AP; Mathios D; Gottschalk C; Nicholas S; Kellett M; Ruzevick J; Jackson C; Albesiano E; Durham NM; Ye X; Tran PT; Tyler B; Wong JW; Brem H; Pardoll DM; Drake CG; Lim M
PLoS One; 2014; 9(7):e101764. PubMed ID: 25013914
[TBL] [Abstract][Full Text] [Related]
11. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4
Khalifa R; Elsese N; El-Desouky K; Shaair H; Helal D
J Immunoassay Immunochem; 2022 Mar; 43(2):192-212. PubMed ID: 34697997
[TBL] [Abstract][Full Text] [Related]
13. Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8
Shaw G; Cavalcante L; Giles FJ; Taylor A
J Hematol Oncol; 2022 Sep; 15(1):134. PubMed ID: 36104795
[TBL] [Abstract][Full Text] [Related]
14. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
15. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients.
Subrahmanyam PB; Dong Z; Gusenleitner D; Giobbie-Hurder A; Severgnini M; Zhou J; Manos M; Eastman LM; Maecker HT; Hodi FS
J Immunother Cancer; 2018 Mar; 6(1):18. PubMed ID: 29510697
[TBL] [Abstract][Full Text] [Related]
16. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
17. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
18. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
[TBL] [Abstract][Full Text] [Related]
19. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
20. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
